President Trump sees Switzerland as doing too little to address its trade deficit with the U.S., a gap he focused on as he imposed a 39% tariff on Swiss goods.
Category: Drugs (Pharmaceuticals)
-
Pill Causes Major Weight Loss in Eli Lilly Trial’s Results
The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the year.
-
How Ozempic Maker Novo Nordisk Lost Its Shine
The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed its fortunes.
-
Switzerland Rushes to Give Trump ‘More Attractive’ Offer to Cut Tariffs
The Swiss government said it had “no indication” the country would be hit with a 39 percent tariff, which is set to take effect this week.
-
Ozempic Maker’s Stock Plunges 20% After Profit Warning
Novo Nordisk slashed its financial forecasts as it struggled to fight off competition in the United States. It also named a new chief executive, who highlighted the “urgency” of the moment.
-
Tariffs on Medicines From Europe Stand to Cost Drugmakers Billions
Many pharmaceutical products made in Europe will face a 15 percent tariff, pinching manufacturers and potentially leading to higher drug prices.
-
UnitedHealth Grew to Be a Leviathan. Then Came the Backlash.
The conglomerate was viewed as one of the most successful companies in America, but patients are enraged and investors have lost faith in its business model.
-
UnitedHealth Grew to Be a Leviathan. Then Came the Backlash.
The conglomerate was viewed as one of the most successful companies in America, but patients are enraged and investors have lost faith in its business model.
-
AstraZeneca Joins Pharma Investment Push in U.S. Amid Tariff Threat
The British drug maker plans to invest $50 billion in the United States as it seeks to appease President Trump.
-
Heath Insurers Are Denying More Drug Claims, Data Shows
Offering a rare glimpse inside the hidden world of rejected insurance claims, new data shows a steady uptick among major private insurers.